Parametric Portfolio Associates’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Parametric Portfolio Associates’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$1.18M	Sell	43,883 -53,886	-55%	-$1.81M	﹤0.01%	2706
2021 Q4	$4.66M	Buy	97,769 +67,555	+224%	+$3.02M	﹤0.01%	1915
2021 Q3	$2.01M	Buy	30,214 +9,459	+46%	+$674K	﹤0.01%	2442
2021 Q2	$1.62M	Buy	20,755 +4,814	+30%	+$356K	﹤0.01%	2544
2021 Q1	$1.51M	Sell	15,941 -9,423	-37%	-$1.12M	﹤0.01%	2958
2020 Q4	$3.09M	Buy	25,364 +849	+3%	+$93K	﹤0.01%	2387
2020 Q3	$2.14M	Buy	24,515 +18,942	+340%	+$1.32M	﹤0.01%	2472
2020 Q2	$360K	Buy	+5,573	New	+$322K	﹤0.01%	3397
2019 Q4	–	Sell	-22,253	Closed	-$837K	–	4015
2019 Q3	$837K	Buy	+22,253	New	+$969K	﹤0.01%	3115

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Parametric Portfolio Associates's TPTX Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Turning Point Therapeutics, Inc. Common Stock (TPTX) stake by 55% in Q1 2022, selling an estimated $1.81M and leaving 43,883 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2706.

Parametric Portfolio Associates first reported a position in TPTX in Q3 2019 and has held it in 9 quarters since. The position peaked at $4.66M in Q4 2021. 155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

Parametric Portfolio Associates held 43,883 shares of Turning Point Therapeutics, Inc. Common Stock worth $1.18M as of Q1 2022.
Parametric Portfolio Associates sold 53,886 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $1.81M.
Turning Point Therapeutics, Inc. Common Stock made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2706 holding.
Parametric Portfolio Associates first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and has held it in 9 quarters since.
Parametric Portfolio Associates's Turning Point Therapeutics, Inc. Common Stock position peaked at $4.66M in Q4 2021.
155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.